All News
Filter News
Found 51 articles
-
Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment
9/16/2022
Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment taking place in Basel, Switzerland from September 21-22.
-
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Eosinophilic EsophagitisTopline data anticipated around year-end 2022
9/12/2022
Revolo Biotherapeutics (“Revolo” or the “Company”), today announced that it has completed enrollment and has fully randomized all patients in a Phase 2a proof of concept clinical study investigating its immune-resetting molecule, ‘1104, for the treatment of patients with eosinophilic esophagitis (EoE).
-
Revolo Biotherapeutics to Present at the Baird 2022 Global Healthcare Conference
9/8/2022
Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Baird 2022 Global Healthcare Conference being held in New York, NY, from September 13-14.
-
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors
9/7/2022
Oncolytics Biotech® Inc. announced the appointment of Jonathan Rigby to its Board of Directors.
-
Revolo Biotherapeutics Awarded Innovation Passport for ‘1805 in the United Kingdom for the Treatment of Moderate to Severe Rheumatoid Arthritis
7/14/2022
Revolo Biotherapeutics today announced that it was awarded an Innovative Medicines Designation, or Innovation Passport, from the Medicines and Healthcare products Regulatory Agency (MHRA) for its immune-resetting drug candidate, ‘1805, for the treatment of patients with moderately to severely active Rheumatoid Arthritis (RA).
-
Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings
5/16/2022
Revolo Biotherapeutics announced that the Company will be delivering presentations at two upcoming medical meetings: the American Thoracic Society International Conference and the Treg Summit.
-
Revolo Biotherapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
5/5/2022
Revolo Biotherapeutics announced that its management team will participate in the LifeSci Partners Immunology & Inflammation Symposium being held virtually May 10-11, 2022.
-
Revolo Biotherapeutics to Participate at SVB Leerink Biopharma Private Company Connect
3/24/2022
Revolo Biotherapeutics, a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced that its management team will be attending the SVB Leerink Biopharma Private Company Connect being held virtually from March 29-31, 2022.
-
Revolo Biotherapeutics To Present New Data at 2022 AAAAI Annual Meeting Demonstrating the Anti-inflammatory Effect of ‘1104 in Acute Respiratory Distress Syndrome
2/25/2022
Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical data will be presented in a poster at the 2022 American Academy of Allergy Asthma and Immunology (AAAAI) annual meeting.
-
Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom
2/4/2022
Revolo Biotherapeutics today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to commence two Phase 2 clinical trials to evaluate its immune-resetting drug candidate.
-
CEO to CEO: Tips for First-time Founders
1/11/2022
BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders. -
Biopharma Executive Perspectives on 2022
1/10/2022
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade. -
Revolo Biotherapeutics Announces the Appointment of Tunde Otulana, M.D., to its Board of Directors
12/27/2021
Revolo Biotherapeutics today announced the appointment of industry veteran Tunde Otulana, M.D., to its Board of Directors.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
Revolo Biotherapeutics Activates Clinical Sites and Opens Enrollment in a Phase 2 Clinical Trial of ‘1104 in Eosinophilic Esophagitis
10/28/2021
Revolo Biotherapeutics (“Revolo Bio” or the “Company”), announced today that it has activated clinical trial sites and opened enrollment in a Phase 2 clinical trial evaluating their first-in-class peptide for the treatment of allergic diseases, ‘1104, in patients with eosinophilic esophagitis (EoE).
-
Revolo Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference
10/26/2021
Revolo Biotherapeutics (“Revolo Bio” or the “Company”), announced today that management will provide a corporate update at the Stifel 2021 Virtual Healthcare Conference, which is being held November 15-17, 2021.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Revolo Biotherapeutics Activates Clinical Trial and Commences Enrollment in Phase 2 Clinical Study of ‘1104 in Allergic Disease in the UK
10/21/2021
Revolo Biotherapeutics announced today that a clinical study has been activated and patient enrollment is underway in a Phase 2 allergen sensitivity study in the UK evaluating the safety and efficacy of its first-in-class peptide
-
Clinical Catch-Up: July 26-30
8/2/2021
With the Alzheimer’s Association International Conference conference last week, there were plenty of clinical trial news and updates. Here’s a look. -
Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK
7/30/2021
Revolo Biotherapeutics (“Revolo Bio” or the “Company”), announced today receipt of Clinical Trial Authorization (CTA) by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK to evaluate safety and efficacy of its first-in-class peptide for the treatment of allergic disease, ‘1104, in a Phase 2 allergen sensitivity study.